231 related articles for article (PubMed ID: 22499062)
21. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
[TBL] [Abstract][Full Text] [Related]
22. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
DU XN; Li Y; Zhang SL; Zhu J; Huang F
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
[TBL] [Abstract][Full Text] [Related]
23. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
24. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
[TBL] [Abstract][Full Text] [Related]
26. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
[TBL] [Abstract][Full Text] [Related]
27. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
28. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
29. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
30. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.
Aydin SZ; Can M; Atagunduz P; Direskeneli H
Clin Exp Rheumatol; 2010; 28(5):752-5. PubMed ID: 20863448
[TBL] [Abstract][Full Text] [Related]
31. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
32. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
[TBL] [Abstract][Full Text] [Related]
33. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
[TBL] [Abstract][Full Text] [Related]
34. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
[TBL] [Abstract][Full Text] [Related]
35. CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up.
Berg IJ; Semb AG; van der Heijde D; Kvien TK; Olsen IC; Dagfinrud H; Provan SA
Ann Rheum Dis; 2015 Aug; 74(8):1562-6. PubMed ID: 25795906
[TBL] [Abstract][Full Text] [Related]
36. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study).
Sellas I Fernandez A; Juanola Roura X; Alonso Ruiz A; Rosas J; Medina Luezas J; Collantes Estevez E; Abad Hernández MÁ; Carrasco Benitez V; Fisac C
Rheumatol Int; 2017 Nov; 37(11):1817-1823. PubMed ID: 28918450
[TBL] [Abstract][Full Text] [Related]
38. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
[TBL] [Abstract][Full Text] [Related]
39. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
[TBL] [Abstract][Full Text] [Related]
40. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
